The GLP-1 Support Patch Pack by PatchAid is not intended to diagnose, treat, cure or prevent any disease
Retatrutide Is Not Yet Approved Explore Proven Medical Weight Loss Options Struggling with weight loss and considering Retatrutide
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial
Men lost more in absolute pounds due to higher starting weights
Subcutaneous Injection Guide | Investigational (Phase 3) Retatrutide Injection Sites Retatrutide (LY3437943) is an investigational triple-agonist GLP-1, GIP, and glucagon receptor agonist injected subcutaneously once a week
If you have type 2 diabetes, work with a prescriber who can monitor HbA1c, fasting glucose, and post-prandial glucose throughout the titration